

**Clinical Trials Summary for out of hours
Important Reference**



Lancashire Teaching
Hospitals

NHS Foundation Trust

Acronym study title	lidERA (GO42784)
Study Details	This is a Phase III, global, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with TPC in participants with medium- and high-risk Stage I-III histologically confirmed ER+ and HER2- early breast cancer.
Principal Investigator PI Sub PI's	Dr Martin Hogg Martin.hogg@lthtr.nhs.uk Dr Elaine Young Elaine.young@lthtr.nhs.uk
Research Nurse Team	Haiyan Huang Haiyan.huang@lthtr.nhs.uk
Drug therapy	Randomised to either Giredestrant Or Endocrine therapy of Physician's Choice (TPC)
In the event that a patient calls this hotline for advise	Please treat as per clinical protocols and inform the clinical and research teams.